Meeting
2020 Genitourinary Cancers Symposium
Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.
Authors
Umberto Basso
Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
Umberto Basso , Giuseppe Procopio , Giuseppe Fornarini , Francesco Massari , Alessandra Bearz , Lucia Fratino , Michele Milella , Maria Bassanelli , Cosimo Sacco , Davide Bimbatti , Elena Verzoni , Mimma Rizzo , Camillo Porta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 632)
Abstract #
632
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2021 ASCO Annual Meeting
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.
First Author: Sumanta K. Pal
Poster
2020 Genitourinary Cancers Symposium
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
First Author: Sam Wong
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff